Biogen to spin off new hemophilia company in Boston area

May 3, 2016 11:31 AM

20 0

Biogen to spin off new hemophilia company in Boston area

The state’s biggest locally-based drug company, Biogen, plans to spin off a new company to be headquartered in the Boston area to oversee its new drugs for hemophilia.

Cambridge-based Biogen (Nasdaq: BIIB) said the company, to be named later, will be headed by John G. Cox, the company’s current executive vice president of pharmaceutical operations and technology. The spin-off is planned to be completed by the end of this year or early in 2017.

Also read: Vedanta to invest 200 bln rupees over 3 yrs to expand aluminium capacity

Read more

To category page

Loading...